Innovation or Stagnation: Challenge and Opportunity on the Path to New Medical Products

March 2004 Innovation or Stagnation: Challenge and Opportunity on the Path to New Medical Products This report provides the Food and Drug Administration's (FDAs) analysis of the pipeline problem the recent slowdown, instead of the expected acceleration, in innovative medical therapies reaching patients. Today's revolution in biomedical science has raised new hope for the prevention, treatment, and cure of serious illnesses. However, there is growing concern that many of the new basic science discoveries made in recent years may not quickly yield more effective, more affordable, and safe medical products for patients. This is because the current medical . . .